Direxion Daily S&P 500 Equal Weight Bull 2X Shares EVEN 深 沪
已收盘 04-21 16:00:00 美东时间
19.6389
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 19.6389
- 总市值 392.78万
- 52周最高 23.2704
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 15.1416
- 委 比 0.00%
- 总股本 20.00万
- 历史最高 25.9114
- 量 比 0
- 振 幅 0.00%
- 历史最低 15.1416
- 每 手 1
- 风险率 0.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多泰和新材新提交“泰栖舍”、“SAFEVEN”等8件商标注册申请
证券之星消息，根据企查查数据显示，近日泰和新材集团股份有限公司新提交“泰栖舍”、“SAFEVEN”等8件商标注册申请。商标申请详情如下：
11-07 21:55
Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference
Integra LifeSciences Holdings Corporation announced that its Chief Financial Officer, Lea Knight, will present at the 2026 UBS Global Healthcare Conference on November 9, 2026, at 2:45 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website. Integra LifeSciences is a global medical technology leader focused on restoring lives through innovative solutions in neurosurgery and tissue reconstruction.
11-06 13:00
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported progress on its cemsidomide trials, with the Phase 2 MOMENTUM trial on track to complete enrollment in 1Q 2027 and initial ORR data expected in 2H 2027. The Phase 1b trial combining cemsidomide with elranatamab has advanced to higher dose cohorts, with data expected mid-2027. C4T also highlighted new biomarker data supporting cemsidomide's potential as a combination therapy in multiple myeloma. Financially, the company re...
11-05 12:00
Autobacs Sets Up ToSTNeT-3 Treasury Share Purchase
Autobacs Seven Co ( ($JP:9832) ) has shared an announcement. AUTOBACS SEVEN dis...
11-04 15:59
安进(AMGN.US)Q3电话会：上调全年营收与EPS指引 管理层预计IMDELLTRA一线放量将非常迅速
本次电话会最受关注的问题不是超预期的幅度，而是IMDELLTRA(塔拉塔单抗)在ESMO大会上公布的一线维持治疗数据。
11-04 09:26
安进盘后跌近2%！Q3营收超103亿美元、利润超预期，17款药品销售两位数增长并上调全年指引
安进盘后跌近2%！Q3营收超103亿美元、利润超预期，17款药品销售两位数增长并上调全年指引
11-04 07:42
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Pharmaceutical Industries Ltd. has entered into a license and commercialization agreement with Samsung Bioepis Co., Ltd. for two FDA-approved immunology biosimilars: infliximab-abda and ETICOVO® (etanercept-ykro). Under the agreement, Teva will obtain U.S. commercialization rights for etanercept-ykro at closing and for infliximab-abda in Q3 2027. The collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial capabili...
11-03 10:00
Magna to Host Investor Day on November 11, 2026
Magna International Inc. will host its 2026 Investor Day on November 11, 2026, in New York City. Key executives, including President and CEO Swamy Kotagiri and CFO Philip Fracassa, will present. The event will include a live webcast accessible via registration on www.magna.com/investorday2026-virtual. A replay and materials will be available post-event. Magna is a leading global automotive supplier with operations in 27 countries.
11-02 13:00
Shell plc publishes third quarter 2026 press release
Shell reported strong third-quarter 2026 results, with adjusted earnings of $10.8 billion, driven by operational performance amid volatile commodity prices. The company completed the ARC Resources acquisition and announced a $5 billion share buyback program. Key highlights include record refining margins, $21 billion in cash flow, disciplined capital spending, and a strong balance sheet with net debt of $39.7 billion. Shell also secured a final i...
10-29 07:01
CLICK HOLDINGS LIMITED CEO JEFFREY CHAN ISSUES LETTER TO SHAREHOLDERS HIGHLIGHTING 61.9% REVENUE GROWTH, SWING TO OPERATING PROFIT AND RECORD NET INCOME OF HK$14.6 MILLION
Click Holdings Limited reported a 62% revenue surge to HK$135.2 million and a net profit of HK$14.6 million for the year ended June 30, 2026. All segments, including nursing, logistics, and professional services, achieved record highs. Nursing revenue grew 62.6%, logistics rose 35.5%, and professional services more than doubled. The company plans to expand into Mainland China, pursue selective acquisitions, and focus on high-margin private nursin...
10-23 12:00
